New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 9, 2013
12:36 EDTAMJ, SIG, AGN, IPXL, JNSHigh option volume; IPXL SIG JNS AGN AMJ
News For IPXL;SIG;JNS;AGN;AMJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 27, 2015
08:34 EDTAGNAllergan says FDA approves Natrelle Inspira breast implants
Subscribe for More Information
February 24, 2015
07:12 EDTIPXLImpax to release guidance when Tower Holdings, Lineage acquisitions completed
Subscribe for More Information
07:12 EDTIPXLImpax reports Q4 adjusted EPS 16c, consensus 12c
Reports Q4 revenue $131.2M, consensus $125.47M. Reports Q4 Global Pharmaceuticals revenue $117.9M. The increase is due to higher sales of several key generic products as well as the impact of customer credits that were recorded in the prior year period of $19.2 million as a result of customer credits relating to certain pricing activities.
February 20, 2015
12:18 EDTJNSMcCulley not leaving PIMCO to go to Janus, CNBC says
07:08 EDTAGNAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
February 19, 2015
07:40 EDTAGNActavis price target raised to $352 from $300 at Canaccord
Subscribe for More Information
February 18, 2015
16:46 EDTAGNOn The Fly: Closing Wrap
Subscribe for More Information
12:31 EDTAGNOn The Fly: Midday Wrap
Subscribe for More Information
09:48 EDTAGNActavis Q4 'exceptional,' taking Allergan name 'wise,' says BMO Capital
BMO Capital says Actavis (ACT) is "firing on all cylinders" after reporting "exceptional" Q4 earnings on the strength of the company's North American Generics and International segment. BMO views the decision to adopt the Allergan (AGN) name as "wise" given the Botox maker's strong reputation. The firm keeps an Outperform rating on Actavis.
07:50 EDTAGNActavis CEO says company gave appropriate guidance to analysts
Actavis (ACT) CEO Saunders said he believes that the company did provide appropriate guidance to analysts ahead of its earnings beat. Saunders sees the Allergan (AGN) deal closing by the end of this quarter or early next quarter. Saunders says tying R&D to a percentage of revenue "makes no sense to me," noting that Actavis will spend about $1.7B on R&D next year. Saunders says will do acquisition if opportunity arises, but not planning for M&A right now. Actavis CEO Brent Saunders is speaking on CNBC.
07:01 EDTAGNActavis announces intention to adopt 'Allergan' corporate name
Subscribe for More Information
06:34 EDTAGNActavis sees Allergan transaction completed in late Q1 or early Q2
February 17, 2015
18:06 EDTAGNPaulson & Co gives quarterly update on stakes
Subscribe for More Information
17:18 EDTAGNPershing Square gives quarterly update on stakes
NEW STAKES: Restaurant Brands International (QSR). INCREASED STAKES: Zoetis (ZTS), and Platform Specialty Products (PAH). DECREASED STAKES: Allergan (AGN). LIQUIDATED STAKES: None.
17:02 EDTAGNSoros Fund Management gives quarterly update on stakes
Subscribe for More Information
13:52 EDTAGNEarnings Preview: Actavis near 52-week high ahead of Q4 earnings report
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use